Runben Biotechnology Co (SHSE:603193) Other Current Liabilities: ¥3 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603193 Runben Biotechnology Co Ltd SHSE:603193
70 GF Score
Price ¥20.54
GF Value ¥28.60
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Runben Biotechnology Co Other Current Liabilities?

Runben Biotechnology Co SHSE:603193 -1.25% 70 Other Current Liabilities is ¥3 Mil as of Jun. 2026. GuruFocus rates SHSE:603193 with a GF Score™ of 70/100 and a GF Value™ of ¥28.60 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Runben Biotechnology Co's other current liabilities for the quarter that ended in Jun. 2026 was ¥3 Mil.

Runben Biotechnology Co's quarterly other current liabilities declined from Dec. 2025 (¥13 Mil) to Mar. 2026 (¥7 Mil) and declined from Mar. 2026 (¥7 Mil) to Jun. 2026 (¥3 Mil).

Runben Biotechnology Co's annual other current liabilities increased from Dec. 2023 (¥7 Mil) to Dec. 2024 (¥15 Mil) but then declined from Dec. 2024 (¥15 Mil) to Dec. 2025 (¥13 Mil).

Runben Biotechnology Co Other Current Liabilities Related Terms

Runben Biotechnology Co Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Runben Biotechnology Co's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Runben Biotechnology Co Other Current Liabilities Chart

Runben Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 5.40 5.26 6.81 15.14 13.11

Runben Biotechnology Co Quarterly Data
Dec19 Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.18 3.34 13.11 7.36 3.01
SHSE:603193
70GF Score
Runben Biotechnology Co Ltd SHSE:603193
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Runben Biotechnology Co Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ¥3 Mil mean?
Runben Biotechnology Co (SHSE:603193) has a Other Current Liabilities of ¥3 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Runben Biotechnology Co.
Is Runben Biotechnology Co's Other Current Liabilities too high?
Runben Biotechnology Co's current Other Current Liabilities is ¥3 Mil. Overall, Runben Biotechnology Co has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Runben Biotechnology Co's Other Current Liabilities compare to PG and CL?
Runben Biotechnology Co's Other Current Liabilities of ¥3 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Consumer Packaged Goods company?
A good Other Current Liabilities depends on the Consumer Packaged Goods industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Runben Biotechnology Co. Runben Biotechnology Co's current Other Current Liabilities is ¥3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Runben Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Runben Biotechnology Co (SHSE:603193) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥28.60, compared to a current price of ¥20.54 — trading 28.2% below its estimated fair value. The current Other Current Liabilities is ¥3 Mil. Runben Biotechnology Co's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Runben Biotechnology Co (SHSE:603193), the current Other Current Liabilities is ¥3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Runben Biotechnology Co (SHSE:603193) Overvalued in 2026?

Based on GuruFocus' analysis, Runben Biotechnology Co stock appears to be undervalued. The current stock price of ¥20.54 is trading 28.2% below its estimated GF Value™ of ¥28.60. GuruFocus considers Runben Biotechnology Co to be Modestly Undervalued.

Key valuation signals for SHSE:603193:

  • Other Current Liabilities: ¥3 Mil
  • GF Value™: ¥28.60 vs. price of ¥20.54 (28.2% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the SHSE:603193 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Runben Biotechnology Co Business Description

Address No. 3, Xinzhuang 5th Road, Guangzhou Economic and Technological Development Zone, Guangdong, Guangzhou, CHN, 510627
Runben Biotechnology Co Ltd is engaged in research & development, production and sales of mosquito repellent and personal care products.
70GF Score

Get the complete analysis for SHSE:603193

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥20.54
Price
¥28.60
GF Value